drugset / Trial / NCT00974350

A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair

NCT00974350

Phase 2 Completed 124 enrolled Durect Nycomed · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication). SABER-Bupivacaine is designed to continuously deliver bupivacaine, a common local anesthetic, for a few days in order to treat local post-surgical pain. This study is testing SABER-Bupivacaine in people having surgery to repair a hernia. The purpose of the study is to measure and compare the safety (side effects), tolerability (ability to tolerate), and efficacy (how well it works) of two different volumes of SABER-Bupivacaine with SABER-Placebo.

Timeline

Start
2007-01
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 2.5 ml Other
Subject Bupivacaine Other / unclassified 5 ml Other

Indications

No indication recorded.